MA50084A - Récepteurs de lymphocytes t qui se lient à des phosphopeptides spécifiques de la leucémie de lignée mixte (mll) et méthodes d'utilisation de ces derniers - Google Patents
Récepteurs de lymphocytes t qui se lient à des phosphopeptides spécifiques de la leucémie de lignée mixte (mll) et méthodes d'utilisation de ces derniersInfo
- Publication number
- MA50084A MA50084A MA050084A MA50084A MA50084A MA 50084 A MA50084 A MA 50084A MA 050084 A MA050084 A MA 050084A MA 50084 A MA50084 A MA 50084A MA 50084 A MA50084 A MA 50084A
- Authority
- MA
- Morocco
- Prior art keywords
- phosphopeptides
- mll
- bind
- methods
- specific mixed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01008—Histamine N-methyltransferase (2.1.1.8)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762553957P | 2017-09-04 | 2017-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50084A true MA50084A (fr) | 2020-07-15 |
Family
ID=63722758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050084A MA50084A (fr) | 2017-09-04 | 2018-09-04 | Récepteurs de lymphocytes t qui se lient à des phosphopeptides spécifiques de la leucémie de lignée mixte (mll) et méthodes d'utilisation de ces derniers |
Country Status (10)
Country | Link |
---|---|
US (1) | US11718658B2 (fr) |
EP (1) | EP3679062A1 (fr) |
JP (1) | JP7387585B2 (fr) |
KR (1) | KR20200052327A (fr) |
CN (1) | CN111278854A (fr) |
AU (1) | AU2018326875A1 (fr) |
CA (1) | CA3073055A1 (fr) |
MA (1) | MA50084A (fr) |
SG (1) | SG11202001319QA (fr) |
WO (1) | WO2019046856A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021216738A2 (fr) * | 2020-04-21 | 2021-10-28 | Intima Bioscience, Inc. | Compositions et procédés de génération d'une réponse immunitaire |
KR20210134116A (ko) | 2020-04-29 | 2021-11-09 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 화합물 |
WO2023148494A1 (fr) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Nouveau récepteur des lymphocytes t |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
WO1996018105A1 (fr) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Recepteur de lymphocyte t monocatenaire |
US5580714A (en) | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
ATE435661T1 (de) | 1997-08-29 | 2009-07-15 | Antigenics Inc | Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
ES2257068T3 (es) | 1998-08-10 | 2006-07-16 | Antigenics Inc. | Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas. |
IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
US6194137B1 (en) | 1999-04-13 | 2001-02-27 | Organ Recovery Systems, Inc. | Method of cryopreservation of blood vessels by vitrification |
JP2002541845A (ja) | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
WO2001014557A1 (fr) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, recepteur de b7-4, et son utilisation |
AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
ES2654064T3 (es) | 2002-07-03 | 2024-03-13 | Ono Pharmaceutical Co | Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1 |
AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
EP1576014B1 (fr) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Anticorps anti pd-1 et leurs utilisations |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
SG155968A1 (en) * | 2004-02-23 | 2009-10-29 | Univ Erasmus Medical Ct | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
DE602005022595D1 (de) | 2004-06-29 | 2010-09-09 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
GB0712670D0 (en) | 2007-06-29 | 2007-08-08 | King S College London | Isolated peptides and uses thereof |
CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
CN104042611B (zh) | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-噁二唑 |
PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
CA2736829C (fr) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Anticorps specifiques de pd-1 et leurs utilisations |
WO2010036959A2 (fr) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
WO2011066389A1 (fr) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Agents de liaison ciblés dirigés contre b7-h1 |
US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
WO2011146862A1 (fr) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Méthodes d'induction d'une apoptose sélective |
WO2011149909A2 (fr) * | 2010-05-24 | 2011-12-01 | Hunt Donald F | Phosphopeptides du cmh de classe i pour l'immunothérapie et le diagnostic du cancer |
WO2012145493A1 (fr) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Anticorps et autres molécules qui se lient à b7-h1 et à pd-1 |
EP2734551B1 (fr) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants d'anticorps monoclonaux immunomodulateurs humanisés |
US8920075B2 (en) | 2011-09-01 | 2014-12-30 | Halo Maritime Defense Systems, Inc. | Marine barrier and gate |
CA2856895C (fr) | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anticorps anti-pd-l1 et utilisations associees |
AU2013222267A1 (en) | 2012-02-22 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
EP2890715B1 (fr) | 2012-08-03 | 2020-12-16 | Dana-Farber Cancer Institute, Inc. | Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation |
CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳-法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
EP3770176A1 (fr) | 2013-05-02 | 2021-01-27 | AnaptysBio, Inc. | Anticorps dirigés contre la protéine de mort programmée 1 (pd-1) |
CA3175360C (fr) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Proteines de liaison a l'antigene qui se lient a pd-1 |
WO2014209804A1 (fr) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Anticorps bispécifiques |
RU2645256C2 (ru) * | 2013-06-26 | 2018-02-19 | Гуандун Сянсюэ Лайф Сайенсис, Лтд. | Высокостабильный т-клеточный рецептор и способ его получения и применения |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
WO2015036394A1 (fr) | 2013-09-10 | 2015-03-19 | Medimmune Limited | Anticorps contre pd-1 et leurs utilisations |
PT3702373T (pt) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
CN104558177B (zh) | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
JP6502959B2 (ja) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | Pd−1抗体、その抗原結合性断片及びそれらの医学的使用 |
US10407502B2 (en) | 2014-01-15 | 2019-09-10 | Kadmon Corporation, Llc | Immunomodulatory agents |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
JP6731346B2 (ja) | 2014-02-10 | 2020-07-29 | メルク パテント ゲーエムベーハー | 標的TGFβ阻害 |
EP3104866A4 (fr) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Méthodes d'activation des lymphocytes t à l'aide d'un polypeptide chimère inductible |
EP3149042B1 (fr) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Anticorps dirigés contre pd-l1 et leurs utilisations |
WO2015195163A1 (fr) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Anticorps totalement humain anti-pd-l1 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
SG11201700672YA (en) | 2014-08-05 | 2017-02-27 | MabQuest SA | Immunological reagents binding to pd-1 |
LT3186283T (lt) | 2014-08-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Kombinuotoji terapija į naviką nutaikytais il-2 imunocitokinais ir antikūnais prieš žmogaus pd-l1 |
MA44907A (fr) * | 2015-09-11 | 2018-07-18 | Agenus Inc | Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation |
-
2018
- 2018-09-04 WO PCT/US2018/049397 patent/WO2019046856A1/fr unknown
- 2018-09-04 MA MA050084A patent/MA50084A/fr unknown
- 2018-09-04 CN CN201880069966.7A patent/CN111278854A/zh active Pending
- 2018-09-04 AU AU2018326875A patent/AU2018326875A1/en active Pending
- 2018-09-04 KR KR1020207009786A patent/KR20200052327A/ko not_active Application Discontinuation
- 2018-09-04 EP EP18782236.6A patent/EP3679062A1/fr active Pending
- 2018-09-04 SG SG11202001319QA patent/SG11202001319QA/en unknown
- 2018-09-04 CA CA3073055A patent/CA3073055A1/fr active Pending
- 2018-09-04 JP JP2020512821A patent/JP7387585B2/ja active Active
-
2020
- 2020-03-03 US US16/807,742 patent/US11718658B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2019046856A1 (fr) | 2019-03-07 |
US20200308246A1 (en) | 2020-10-01 |
SG11202001319QA (en) | 2020-03-30 |
JP7387585B2 (ja) | 2023-11-28 |
AU2018326875A1 (en) | 2020-03-19 |
CN111278854A (zh) | 2020-06-12 |
EP3679062A1 (fr) | 2020-07-15 |
KR20200052327A (ko) | 2020-05-14 |
CA3073055A1 (fr) | 2019-03-07 |
US11718658B2 (en) | 2023-08-08 |
JP2020532304A (ja) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47265A (fr) | Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers | |
MA53981A (fr) | Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation | |
MA44608A (fr) | Récepteurs des lymphocytes t | |
MA49236A (fr) | Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant | |
MA49503A (fr) | Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant | |
MA47359A (fr) | Récepteurs de lymphocytes t à appariement amélioré | |
MA43025A (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 | |
MA50084A (fr) | Récepteurs de lymphocytes t qui se lient à des phosphopeptides spécifiques de la leucémie de lignée mixte (mll) et méthodes d'utilisation de ces derniers | |
MA45976A (fr) | Récepteurs de lymphocytes t et thérapie immunitaire les utilisant | |
MA49270A (fr) | Récepteurs de liaison à l'antigène améliorés | |
MA43017A (fr) | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf | |
MA40721A (fr) | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA50584A (fr) | Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA43372A (fr) | Compositions à greffe de cytokine-anticorps et procédés d'utilisation pour l'immunorégulation | |
MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
MA50651A (fr) | Récepteurs de lymphocytes t reconnaissant p53 mutée | |
MA39708A (fr) | Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain | |
SG11202103609YA (en) | T-cell receptors and uses thereof | |
MA56548A (fr) | Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation | |
IL280347A (en) | Systems and methods for providing en route rerouting | |
MA52228A (fr) | Composés agonistes du facteur de différenciation de croissance 15 et leurs procédés d'utilisation |